Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
How Has the Controlled Release Drug Delivery Market Size Evolved Over the Last Few Years?
The market size of controlled release drug delivery has seen a significant increase lately. It’s projected to expand from $65.44 billion in 2024, up to $72.34 billion in 2025, with a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this growth during the historical period include the development of advanced drug delivery systems, the initial use of polymer-based formulations, the introduction of microencapsulation techniques, the advent of transdermal delivery, regulatory permissions, and the establishment of standards.
In the coming years, the market size for controlled release drug delivery is set to experience swift expansion, reaching $117.24 billion in 2029 with a compound annual growth rate (CAGR) of 12.8%. This projected growth during the forecast period is mainly due to the shift towards personalized medicine, inclusion of advanced technology for patient’s comfort, development of biologics and biosimilars, market development in emerging regions, and improvements in polymer science. The major trends anticipated during this forecast period encompass biodegradable and biocompatible materials, advancements in nanotechnology, personalized medicine and targeted therapies, progress in implantable devices, and novel encapsulation techniques.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Are the Key Drivers Fueling Growth in the Controlled Release Drug Delivery Market?
The upsurge in chronic or noncommunicable diseases such as heart disease, cancer, and diabetes is predicted to fuel the expansion of the controlled release drug delivery market. These diseases, often lasting more than a year, necessitate ongoing medical treatment and may restrict daily activities. The importance of controlled-release medication delivery in managing chronic diseases cannot be overstated. Prolonged release drug formulations are crucial for patients with chronic diseases that require extended treatment and those located in regions with scarce healthcare resources and accessibility.
For example, a report from the World Health Organization (WHO), a health-focused agency based in Switzerland, disclosed in September 2022 that chronic diseases claim 41 million lives annually, constituting 74 percent of all global fatalities. Tragically, 17 million people succumb to chronic diseases before reaching 70. More alarmingly, 77 percent of deaths attributed to chronic diseases happen in low to middle-income countries, and these figures are predicted to escalate in the future. Consequently, the increasing prevalence of chronic diseases is spurring the growth of the controlled release drug delivery market.
Which Key Segments Are Driving Growth in the Controlled Release Drug Delivery Market?
The controlled release drug delivery market covered in this report is segmented –
1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal And Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Personal, Research, Other End Users
Subsegments:
1) By Wurster Technique: Spray Coating, Fluid Bed Coating
2) By Coacervation: Simple Coacervation, Complex Coacervation
3) By Micro Encapsulation: Polymer-Based Micro Encapsulation, Lipid-Based Micro Encapsulation
4) By Implants: Biodegradable Implants, Non-Biodegradable Implants
5) By Transdermal: Microneedle Patches, Reservoir Systems, Matrix Systems
6) By Targeted Delivery: Nanoparticles, Antibody-Drug Conjugates, Liposomes
7) By Other Technologies: Osmotic Pumps, In Situ Gelling Systems
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
Which Emerging Trends Will Impact the Controlled Release Drug Delivery Market in the Forecast Period?
The controlled-release drug delivery market is increasingly witnessing a trend of technological innovation. Leading companies in this market are embracing new technologies to maintain their competitive edge. For example, in March 2022, Evonik Industries AG, a pharmaceutical firm based in Germany, introduced UDRATEC SoluFlow. This innovative microparticle technology can enhance the solubility of active elements in oral drug formulations, which existing production methods have been unable to achieve. As part of Evonik Health Care’s portfolio of oral drug delivery system solutions, EUDRATEC SoluFlow complements existing products such as EUDRAGIT functional polymers, EUDRACAPTM ready-to-fill functional capsules and other technologies and services aimed at enhancing medication performance.
Which Geographies Are Leading the Expansion of the Controlled Release Drug Delivery Market?
North America was the largest region in the controlled release drug delivery market in 2024. The regions covered in the controlled release drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Who Are the Top Companies Dominating the Controlled Release Drug Delivery Market in 2025?
Major companies operating in the controlled release drug delivery market include Johnson & Johnson Services Inc., Merck & Co. Inc., Alkermes plc, Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel LLC, GlaxoSmithKline plc, Bayer Healthcare LLC, Collegium Pharmaceuticals Inc., GE HealthCare Technologies Inc., Adare Pharmaceuticals Inc., Allergan plc, Novartis AG, Lonza Group AG, Colorcon Inc., SKY Pharmaceuticals Pvt. Ltd., AstraZeneca plc, Biogen Inc., Orbis Biosciences Inc., Alza Corporation, MicroCHIPS Inc., Endo International plc, Heron Therapeutics Inc., Intellipharmaceutics International Inc., Ipsen Biopharmaceuticals Inc., Luye Pharma Group Ltd., Medtronic plc, Nektar Therapeutics, Novo Nordisk A/S, Ocular Therapeutix Inc., Pacira BioSciences Inc., Progenity Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., Vectura Group plc, West Pharmaceutical Services Inc., Zosano Pharma Corporation, Zynerba Pharmaceuticals Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…px?id=9930
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
